Cabozantinib for neurofibromatosis type 1–related plexiform neurofibromas: a phase 2 trial

Keyphrases

• Neurofibromatosis Type I 100%
• Phase II Trial 100%
• Cabozantinib 100%
• Plexiform Neurofibroma 100%
• Adverse Events 66%
• Neurofibromatosis Type 1 (NF-1) 50%
• Partial Response 50%
• Disease Progression 16%
• Clinical Trials 16%
• Magnetic Resonance Imaging 16%
• Tyrosine Kinase 16%
• Dose Reduction 16%
• Pharmacokinetics 16%
• Neoplasms 16%
• Tumor Volume 16%
• Quality of Life 16%
• Cell Lineage 16%
• Safety Efficacy 16%
• Quality of Life Assessment 16%
• Differential Modulation 16%
• Safety Activity 16%
• Sarcoma 16%
• Gastrointestinal Toxicity 16%
• Pain Interference 16%
• Patient-reported Outcomes 16%
• Cre Mice 16%
• Neurofibromatosis 16%
• Biologic Activity 16%
• Tumor Volume Reduction 16%
• Daily Life 16%
• Trial Participants 16%
• Tumor Pain 16%
• Lesion Volume 16%
• Pain Intensity 16%
• Global Quality of Life 16%
• Target Lesion 16%
• Hypothyroidism 16%
• Pain Improvement 16%
• Palmar-plantar Erythrodysesthesia 16%
• Therapy Discontinuation 16%
• Circulating Endothelial Cells 16%

Medicine and Dentistry

• Cabozantinib 100%
• Neurofibromatosis 100%
• Plexiform Neurofibroma 100%
• Neoplasm 66%
• Adverse Event 66%
• Neurofibromatosis Type I 50%
• Quality of Life 33%
• Cytokine 16%
• Clinical Trial 16%
• Magnetic Resonance Imaging 16%
• Protein Tyrosine Kinase 16%
• Disease Exacerbation 16%
• Patient-Reported Outcome 16%
• Drive 16%
• Kinase 16%
• Gastrointestinal Toxicity 16%
• Pharmacokinetics 16%
• Cell Lineage 16%
• Hand Foot Syndrome 16%
• Drug Dose Reduction 16%
• Hypothyroidism 16%
• Target Lesion 16%
• Circulating Endothelial Cell 16%
• Connective Tissue Cancer 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Cabozantinib 100%
• Neurofibroma 100%
• Neurofibromatosis 100%
• Neoplasm 66%
• Adverse Event 66%
• Neurofibromatosis Type 1 50%
• Clinical Trial 16%
• Cytokine 16%
• Protein Tyrosine Kinase 16%
• Disease Exacerbation 16%
• Hypothyroidism 16%
• Gastrointestinal Toxicity 16%
• Hand Foot Syndrome 16%
• Connective Tissue Cancer 16%
• Pharmacokinetics 16%